BioSpace News Archive

Policy

Seagen Loses Patent Battle against Daiichi Sankyo as Merck Waits in the Wings

As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.

August 15, 2022
·
3 min read
·
Mark Terry
Drug Development

Following Failed COVID-19 Treatment, NRx Prioritizes Bipolar Depression Candidate, NRX-101

During the second quarter, NRx reactivated the development of NRX-101 and intends to initiate a Phase IIb/III study for ASIB by the end of this year or early 2023.

August 15, 2022
·
3 min read
·
Alex Keown
Career Advice

Remote Job Options in the Life Science Industry

To help you in your job search, here are just a few of the remote job options in the life science industry, along with the qualifications and skills necessary to be successful in each role.

August 15, 2022
·
5 min read
·
Franklin Carpenter
Drug Development

Why is the Quest for Universal Flu and COVID-19 Vaccines Taking so Long?

After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.

August 15, 2022
·
4 min read
·
Gail Dutton
Drug Development

Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial

Novartis released results from the Phase III CANOPY-A trial, showing that its canakinumab candidate failed to meet its primary efficacy endpoint in adult NSCLC patients.

August 15, 2022
·
3 min read
·
Tristan Manalac
Study: SOD1 Protein could have Therapeutic Implications Beyond Familial ALS

In a recently published study, researchers found that the link between the SOD1 protein and Amyotrophic Lateral Sclerosis (ALS) could extend to all types of the motor neuron disease.

August 15, 2022
·
2 min read
·
Katherine Davis
Drug Development

UK Approves World’s First Omicron-Specific Booster by Moderna

The U.K’s MHRA has granted conditional authorization to Moderna’s newest vaccine candidate, making it the first Omicron-specific COVID-19 booster vaccine approved by a regulatory agency.

August 15, 2022
·
3 min read
·
Vanessa Doctor, RN
Business

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Quarterly total net revenue of $28.6 million ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 Conference call scheduled for 8:30 a.m. ET TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, today reported financial results for the Second Quarter ended June 30, 2022.

August 15, 2022
·
12 min read
Business

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Gracell Biotechnologies Inc. today reported second quarter unaudited financial results for the period ended June 30, 2022, and provided corporate updates.

August 15, 2022
·
13 min read
Business

WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2022 RESULTS

Willow Biosciences Inc. has released its financial and operating results for the three months ended June 30, 2022, reporting significant progress to its operational platform, leadership and strong liquidity.

August 15, 2022
·
9 min read